BCPC - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to the Balchem Corporation Quarterly Conference Call for the Fourth Quarter 2019 Financial Results. At this time, all participants will be in listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that this conference is being recorded.

turn over I'll Chief Martin time, Officer. Financial this the to conference Bengtsson, At Mr. now begin. may you Bengtsson,

Martin Bengtsson

Thank and to me call joining ending Bengtsson, our Chairman, of you, Chief you our Corporation is December conference thank Rob Balchem and and name CEO, call Ted good XXst, morning Financial XXXX. Harris, this is the Officer; with morning for discuss My results and the President. quarter everyone Martin for this hosting

at counsel, release belief our which I auditors, likely of this advice risks SEC, our This time, expectation concerning like the statements. will the involve that does and read to or Following events reflect Balchem's statements would and uncertainties. or future contain forward-looking forward-looking contain

in cause correct various risks Form forward-looking statements We to no results and Balchem's can our give will factors factors and reflected assurance expectations could XX-K. materially expectations that from differ in including identified prove the

qualified statement. entirety are by statements their cautionary this in Forward-looking

I President. Ted will now turn Chairman, CEO, to our Harris, the call over and

Ted Harris

Martin. Thanks welcome call. conference our to morning Good and

Before quarter, over few significant I a to for of reflect some on minutes the the get year. past Balchem team accomplishments into the would achieved like I the

And with flow net Financially, record from $X.X earnings million million three Nutrition strong adjusted record X.X% drove at performances was X.X% and $XXX record in for increase XXXX Specialty million, all $XXX.X growth strong and or Animal the sales of Products an Nutrition delivered prior cash Health, in of These the adjusted or of million $XXX.X delivered million compared remained $X.X increase million to & sales $XX.X sales $XX.X of of Balchem. year year, from of XXXX. sales free million our EBITDA another year. prior four Human an XXXX. year-over-year in we segments. & Health,

we good had a Strategically, also year.

our world the health to and we nutritional needs company, a striving for the the place of as are same with strong time, and innovative operating providing healthier of solutions world excellence make stakeholders. at all a the As by stewards

making and awareness. And science mineral, the and progress amino making external and We new Plant acid our studies, on Animal, and new advancement Human, are future choline, for difference of our a in development, product development Nutrition investments nutritional franchises. are understanding

as chelated notably, of launched Health. chelated a several a line products a compaction we including that result the mineral new are Nutrition Most Human market minerals developments, internal for & improved Citrate and difference Malate silica-free Calcium of an to making

for to micronutrients pet our organic foliar we of And expanded applied our nutrition. methionine organic market treats. We inclusions sensory superior and the AminoShure product chelated of potassium out our an XM, launched animal line enhanced And for PetShure we line that stability. companion include introduced fill feed rumin-protected products for bioavailability to delivers micronutrient next-generation plant

are of Animal work nutrition acid and to development autism, monogastric treatment the a the of and ruminant for chelates, invention the research our between development At synergies exploration our are with Nutrition and making doing the studies a are the including cognition, DHA the unique species and all mineral, & amino & time, investing a broad-ranging magnesium the partners of absorption, of Human we and on same child also we choline, Health biomarker, of choline next-generation the difference within Health. external for choline benefits explore in of work within Nutrition

acquisitions front Chemogas and of We XXXX May remain December. active of Inc. River Brand on completing the the in also acquisition Zumbro in

customers' other that been and oxide completed we for have Specialty our synergies performance have Products needs leverage products of to acquisition We ethylene a segment services the into effectively global this and as business identified realizing we integration create our Chemogas worldwide. gases

the further nicely the capabilities. our and also progressing enhance acquisitions extrusion and performance food synergies. contributed industry, we of realizing beverage and XXXX already Both financial high-protein Zumbro's products solutions And manufacturing Zumbro positioning in unique our and have some capabilities. strategic in through these to particularly of of integration been our We portfolio and

progressed systems This we $XX consolidate into growth perspective, our effort corporate Dynamics our the is XXX. ERP and efficiency Microsoft five of significantly one to million for critical operational the a company. From continued initiative

of implementation with XXXX. across of a in to new all to After amount pleased forward system. the XXXX implementation the year very sites, work, the and started of ERP full and we in significantly approximately network in of earnest we the our we revenues users This stage with progress been manufacturing implementation are businesses look ending but planning, tremendous progressed now as and XX% on has our to-date

with executed a also associated a both offset our dilution of provide shareholders. plan incentive our the to and modest We stock return capital equity program to repurchase

focuses We repurchase the stock deployment This is shares dilution approximately XXX,XXX largely of repurchasing $XX.XX program an average primarily component investing offset that on cost by per share. of our capital and at return, overall an strategy dividend growth attractive our strategic shareholders. M&A and growth down appropriate, our balance provide strong in and organic our that to sheet augmenting opportunities retaining growing a where organic debt paying through maintaining one

first Balchem captures in social XXXX which its lastly, environmental, our Sustainability the governance ESG and to managing or Report performance. And company's released commitment

XX stakeholders. needs the Sustainability and our in facilities our operating the formal for solutions nutritional spent While of engaged businesses and of this of have is expectations innovative passionately while world, we developing past all our years Report, delivering and health the first the to

and the progress All we commitments into further is strong and vibrant a and company the our our stronger communicates foundation that for future. and in all, to on and Our report another place forward making year more strategically XXXX these a into ESG continuing both healthier contributes meaningfully our Balchem beyond. look initiatives financially and have XXXX in the look and to We world making build to to shares this objectives. ambition momentum forward to we built

of in $X.XX per net consolidated million, of $XX.X reported resulted quarterly to with the a record GAAP $XXX.X income XXXX. or of on morning sales regard which This Now million net share basis. quarter fourth quarter we fourth

items Our $XX.X detailed comparative as the fourth versus or performance of million earnings release quarter period. our morning and evaluation facilitate operating net earnings prior exclude $X amortization in per to non-GAAP share of year other tax-adjusted of million $X.XX this non-cash

These represent net prior record of quarter per per of million share share an non-GAAP increase year the $X.XX $XX.X million or $X.XX or or million with $X.X of earnings share. $X.XX per compared $XX.X

free operations million. We million cash of also quarter from the for $XX.X $XX delivered flows quarterly flow with XXXX quarterly fourth cash of

sales in in $XXX.X Health & our Industrial year. our to Our fourth by Health segments Products and related segment four which to Nutrition and were where volumes Specialty And fracking the quarterly than were three segment in sales X.X% We all-time quarter record quarterly segments. Nutrition prior record Human net fourth, offset significant Animal sales gas our prior of remained quarter. comparable compared sales higher decline achieved growth of & million year partially the oil in low our Products with

was The impact of due point euro exchange weaker XX to $X.X the a sales year-over-year basis negative driving negative foreign impact our a to sales growth. our million to

for with or margin the up year. compared in gross $X dollars million X.X% consolidated QX $XX.X million same prior the period million of $XX.X were Our

sales and in certain of of costs. Our in was consolidated XX.X% was The raw QX XX.X% XXXX. basis basis points to lower material margin XXX percent increase primarily from up the mix gross XXX point quarter, due

debt Health quarter to the and and million was operating as due a fourth for expense operating year. the acquisitions, The XXXX in to bad $XX.X to expenses transaction were principally segment. Chemogas costs, and prior higher & Consolidated in $XX.X the integration incremental Zumbro Nutrition related restructuring compared charge million increase non-cash Human expenses the increased

Excluding non-cash with of operating of amortization expense $XX.X million, intangible were or XX.X% operating assets of associated $X.X expenses million sales.

XX.X% leveraging operating existing from controlling SG&A quarter focus operations infrastructure. GAAP a on to compared year. decrease prior the were forward, of and $XX.X Looking continue our will expenses we for million to $X.X million, fourth tightly our earnings or

the detailed our was above adjusted operations an prior million the $XXX.X of million or net $X.X compared with expense release overall the and to X.X. leverage million of posted basis million debt -- a XXXX. on million quarter ratio the XX year. quarter of morning, fourth $XX.X fourth Adjusted million earnings $XX.X was $XX.X $XX as X.X% in $X.X $X.X of down an our this was million in X% debt of earnings or XXXX million from for On EBITDA Interest were in net basis,

clarifying for year fourth XXXX X.X% effective regulations, net tax related tax rates tax the particularly were million, state XX.X% and respectively. attributable quarter quarter to $XX.X at Consolidated prior tax items, effective and income in reform company's quarter. taxes. decrease R&$, credits from certain lower incremental the XXXX to primarily discrete up X.X% rate the closed The the The and is

flat with $X.XX. year's into share result translated This of for per quarterly $X.XX the year net diluted quarterly earnings current income of comparable net last

$X.XX cash release, detailed year out closed with $X.X basis On our generated or diluted net were fourth quarter million share compared the flow earnings million $X.XX quarter an as the adjusted adjusted XX.X% per diluted or share, we balance We million a the earnings per million $XX.X quarterly and free of quarter. sheet. with on or $XX.X million in and cash $XX.X up prior of our in $XX.X

turn our detailed the the for call to results I'm going to over of now through to back go each segments. Martin

Martin Bengtsson

you, Ted. Thank

was from by increase Health sales quarter, record year. achieved an offset partially For million, & Human sales lower volumes. or Systems million higher business, increase the prior all-time our in primarily Cereal driven the sales Ingredient by X.X% quarterly The segment $XX.X Nutrition our of $X of Solutions

Dean also million, a to a product Nutrition compared Human largely manufacturing the the underperforming discrete of from fourth expenses delivered of attributable certain offset associated operations inefficiencies, decrease Our prior year, a and to & debt bad Health items non-cash or by exiting partially including quarter aforementioned Foods primarily earnings $X.X bankruptcy higher restructuring with million XX.X% sales. of charge the due $X.X the several line, to small segment higher

acquired assets million, this $X.X operations Excluding were associated million and prior in cost or earnings with $XX.X $X.X expense of from inventory million of of $X.X of the to restructuring $X compared adjustment million, non-cash the of valuation adjusted $XX.X an XX.X% amortization for quarter. of year a segment million million intangible effect decrease

compared all-time within The Our Health $X.X increase sales quarterly ruminant segment delivered year. sales driven Animal both and prior X.X% an higher mix improved was of and monogastric or record product the by businesses. in Nutrition to & million, primarily our increase million volumes of $XX.X

and nutrition health Ruminant which unique of in not encouraged a is to dairy for XXXX sales were of approximately us period seen by environment long creating market our a from products of change prices for the dairy healthier to milk economics, and X% welcome Class levels rise a the line we're since cows. up III poor

impact The to negative but is were this term. expect price X.X% continue up fourth quarter, in & X%, of in in Animal to most to exchange pressure Nutrition year-over-year experience we million segment foreign the impact approximately our continue a $X.X impact negative driving notable Monogastric growth. with in we and competitive Europe Health the volumes near a

Animal from the XX.X% all-time to due European Nutrition & Health certain quarterly year the prior raw operations million, continued the higher and monogastric record of costs up primarily an $X.X competitive partially from material $X.X by aforementioned, sales pressures the million on lower in quarter, or earnings business. offset were pricing

was Products higher of segment the $XX.X of to higher sterilization The sales the and volumes delivered sales business. device medical $XX.X both offset the nutrition in with XX.X% million for partially quarter sales, oxide Specialty ethylene plant due of the as driven lower prior record product for year million Our of by Chemogas quarter. legacy contribution market compared fourth increase by

X%. achieved an Products quarter, year segment operations earnings quarter increase million of versus $X.X record of the in Specialty $X.X also $X.X or from million prior fourth million

with prior increase for an to of quarter XX.X% amortization assets associated in the of million non-cash the from million the this of of segment $X.X million, earnings $X.X million or $X.X effect Excluding operations $X.X were expense fourth intangible adjusted compared year

quarter, $X.X choline operating The Industrial the used shale aforementioned primarily sales and or by mix Chemogas $X.X reduced acquisition. due increase our due primarily by Products applications. and of decreased derivatives XX.X% million from of choline was year sales, driven offset prior sales to segment In partially million fracking the expenses higher higher to the in

activity, We where eliminating demand recycle costs lower in continue to within fracking operators as starting segments, additives also reduce to not and well but slower to fracking due experience fluids, Industrial the more Products possible order cash. only significantly as to preserve to due

expecting not We're the recovery activity any seeing in any we're this fracking the at not and short in recovery time term.

cautious we market. about historically cyclical this As such, remain

to Our quarter earnings volumes. due decrease the compared from Products the million, $X.X were year prior $X.X for operations Industrial with the segment sales a lower million of

call the closing turn over I'm Ted now going back to remarks. to for some

Ted Harris

while strong quarter cash Health. our certain market four previously revenue with & flows Martin. across Nutrition consolidated in earnings fourth and conditions Thanks of items and the cost year-over-year three from segments the operations, oil within In we net delivered gas challenging and growth noted Human facing discrete

Our net X.X debt revolving provide capitalize of us adjusted and times organic both facility on and EBITDA credit the opportunities. leverage strong inorganic ratio growth balance flexibility sheet to

we we healthy over We to have strong markets generate growth the we are positions believe to positioned the serve within come. and well years

pleased value-creating We our and the our growth QX continue opportunities. company on strategies, with our and in strengthening seeking are made XXXX. to cost focusing management And key by initiatives exercising progress throughout core on strategic disciplined work we'll acquisition on

Martin? back who And now over open to the questions. call up hand to call Martin for will I'd like the

Martin Bengtsson

questions. we this the open up for formal of now This call conference. At point the Ted. the will you, Thank portion concludes

Operator

Thank you. you. Thank Instructions] [Operator

question Seaport Global. Hundley of proceed your first is the today from with with coming Brett Please question. Our line

Brett Hundley

good guys. Hey, morning,

Ted Harris

Brett. Hi,

Martin Bengtsson

Hi, Brett.

Brett Hundley

we quickly them few a couple questions move housekeeping have I about HNH I questions, want segment. ask because can you of do to if the through pretty a

during first And, question on if that for you to flip both maybe around give your be that's range? which you the the just with because would EPS guidance EBITDA so in my can Martin XXXX? present to intend to the grow expectation optics that at that formal but a don't math your want for line. by But play of about expectation if is would case tax could know that headwind I going least XXXX XX% you EPS XXXX, So is $X.XX to still to the I

Martin Bengtsson

on that, we comment I the me what let would around first. know where we Brett, the rate rate, on tax for say see is XX% today, tax based XXXX.

in of a know tax rate some were obviously we're due planning sit we top to today, our we're rate would whether our some saw for we both XXXX. growth we able and perspective. I about line where to on outlook bottom your On I would just a XXXX what to line say, for our growing in we terms much well in EBITDA, regarding, items. drive positioned But from if You XXXX, putting take, discrete question quite in nice lower plan XX% today

Brett Hundley

Chemogas. in put Thank Can by Specialty the on Chemogas was segment the one, you million. that. other the you top for wanted I $X.X same explain that you contribution contribution Your net-net And about to ask you in from QX on ballpark? line? Would grew that

Martin Bengtsson

a Where Yeah. Chemogas contributed to had bit approximately $X million you round to the the of a closest you of full part plant was products. on million. downtick nutrition little Specialty

Brett Hundley

manufacturing Foods little so And first into I'll But want on HNH. get understand the questions back item a also calling queue. my on the quarter. for discrete Thank the Perfect. about inefficiencies. Okay. you Perfect. and and and HNH in go ask out try then – during bit my maybe the Dean bankruptcy then to better question that I

There they are some at Dean would But subsequent manufacturing And circumstances about them And I'm to buy I'm exposure quarters? your else – there assets. DFA it that might customer. the where all the and expect confidence sorry in we not would your to the or item can around have changed the us you a profile or they you subsequent is up all something you secondly, tied inefficiencies could asking in that specific talk exposure implementation, some come changed that, see then see that you ERP question all? quarters give particular a be here? away risk at you given go have the in to that some discrete given So have the lined financing, announcement? at

Martin Bengtsson

Yeah.

comment I'll the me well. first, quickly bad let chime Brett debt Ted and as Let in on

We're In of changed to exposure the now. any our with so moment. Dean advance still need at obviously we terms have delivering paying but risk terms not taking product since they them the they're in we're ingredients, us the

them or any exposure to up building that's in not case we're them. this acquire – there's to So looking DFA

question do efficiency ERPs. and would to say anything is the part It would our – manufacturing of the second high-yield implementation. the the the within and quarter, number addressed no. quarter fourth solutions the have with into call particularly related business material we're of in spec of ERP I We've had fourth here, through the unusually no which result these quarter. ingredient the a it going We to and the still I working in doesn't losses, them And it ERP? a was of here early in of some first

in would we to as So foreseeable here expect future. up running back be and normal the

Ted Harris

of have as We our have least, We to us Dean again I'll is was about for business at rare of get we Human we occurrence debt, risk or – that bad bad critical to us million some hope And vendor already our as business. what in kind costs and Nutrition We about rely a We Foods. the Yeah. don't had further about numbers of Dean in describe add-on do to I Foods debt, That have round Health comments. million. – on with highly Martin's some like spoke associated additional don't back $X really may $X a we that which in would at hope & unusual time DFA. just QX. behind unusual over to any very

of additional event. we that the made the add really some underperforming exit had that piece We to a decided try which needed restructuring we a was plant This to to room It's grow million is very of to $X and a of because part equipment product. business, a a non-cash specific business. just really new

$X driven those about completely Obviously, us. million. that do they significant were But the again Martin million over covered which a the – be And where efficiencies were. manufacturing will behind we QX. of to in was I think will we the rounding they well. hit And had we them course $X those are then out us. partially internally and we what and believe address They understand behind issues were full QX And

Brett Hundley

helpful. really that's Okay,

QX rate there that improvement And a at the QX to be we run seasonality maybe full that relative will QX last some the margin, the we and so maybe back there should in to part summarize can just Is we potentially any then QX. and that QX kind in of be see maybe normal build if bridge from I margin including QX fair? model, in can

Ted Harris

Absolutely.

Brett Hundley

Okay.

just back in in before that Okay, perfect. of the the question I acquisition I about I And Ted. interesting. And your nothing business segment. HNH the was BXB new. really queue is Zumbro to last in signifies I jump my the ask it thought what nature sense of the then mean, wanted And Zumbro

ways. have guys You call think as it in I I'll in at multiple co-manufacturing And I a been business for kind while now. what your of look involved HNH about

guys are you operate business, like. private think I the BXB BXB you and you almost label producer as also to have And a you where sell options moving retail manufacturers can have into that this where into set, business you where then the co-manufacturer. food ingredients seemingly and

growth Do more further more where a you margin I there? on opportunities there? sense. Balchem a that co-man it hope given and you think the potential and see Zumbro potential does move I'm signify that makes question well describing maybe profile even side, And by

Ted Harris

think more a Brett. towards the move it signifies acquisition that But co-manufacturing. I don't Yes Zumbro does,

One we snacks, product so they forth. is a way we're high-protein some view for the engaged. products. we products in I unique and an think had bars They're And Zumbro extruded offering think unique products extrude acquisition area really and the where snack capabilities twofold. have already they I extruding was

market struggled before. we've into to side that get the And of

offering not capabilities this market. that product of allow market. would offering a other an us an and example unique it snack snack be capability It's our it the that us to example pre-manufacturing. synergistic to liked the And we thought have to So of and really a is manufacturing broader we with and

those the there an performance And and operating Zumbro integrating co-manufacturing was out is it do we somewhat, by at were of a two the looked ultimately lenses I strategic and there market guess opportunity the it. I costs the really And the Yes of with consolidate solely improve larger Balchem. to strategy Zumbro part opportunistic take through decided that this. think acquisition the to

Brett Hundley

jump back great. for the queue. I’ll in That’s Thanks the clarification.

Ted Harris

Thanks.

Operator

with Next Ram Wainwright. question of with the line question. your is Selvaraju from proceed H.C. Please

Ram Selvaraju

Hi. Thanks that questions. taking with wondering much what regarding I start any? the we surrounding could for you Maybe was off metrics Zumbro. just had very my disclosed acquisition if

Ted Harris

this kick just can Martin off I'll you maybe then and specifics. So give

not to had we but an with the owners specifics to So to you former now. disclose agreement some are initially we specifics announce of free signed Zumbro,

go can Martin of share you ahead So and some with numbers. the

Martin Bengtsson

enterprise Zumbro of absolutely. Yes. The basis for million. debt-free a on value sort cash-free we $XX paid No was

EBITDA about X.X for So of that XXXX and them represents a multiple times nine times adjusted sales.

a sub-XX this paid So multiple for that it's acquisition. we

We a synergies X% XXXX. that Zumbro clear accretive in majority expect we but And of in perspective do pretty to us have an in we of be EPS of is drive a too. to the cost their GAAP and to from revenues expect synergies, sight adjusted that both of line about terms synergies

Ram Selvaraju

Okay, any us subject synergies, the on we're the you if and very on synergies the of just acquisition an And and of picture integration? in wake while projected perfect. wondering realized was helpful. updated That's I Chemogas give if could the

Martin Bengtsson

Sure.

Ted Harris

Yes.

Martin, again, you can So,

Martin Bengtsson

Yes, I can.

Ted Harris

that Clarify sales a in – would think the middle we And amount. X% to I of of January that. relative really But run similarly we about rate late I synergies. operating of had say January, at said we're

of some can think us in took Martin you the it maybe it's at we're here to get so And operating give But I specifics? run costs that the early remainder XXXX out. QX, rate.

Martin Bengtsson

Yeah. factual No that's that is -- a statement.

Ram Selvaraju

that… And Okay.

Ted Harris

and purchasing but total costs coming, synergies. do And really that some And yeah. costs, largely really costs. already, combination up They're to number a cost so the have of of added the synergies Okay. sales was we organizational have

Ram Selvaraju

additional in with for to combining additional wondering, the couple supplement Okay. existing your if you're possibility And of supplement courses light potentially particularly seeing I quick by Asia ones. whether of incorporation for supplement of regimens might that of particularly in products, recent or been the choline internationally you a Pacific be some was of to potential just products interest the sold And think enhanced them if other segment data internationally for could that's you existing of HNH clinical collaborations those synergistic be incremental HNH region. the folks with or on choline into because example advocating business then regimens. within could presented that there your comment for

Ted Harris

speak tend one we global. the and be region And to with we're Yeah. have on opportunities been data the see being The world. short is the They opportunity global. absolutely. run in developed that answer that -- hand and strong may region clinical another opportunity believe Europe foremost we think but Pacific is do is in Asia We that developed. companies has prenatal we in fairly based And the as in be leading the the working really fairly vitamin being at products first regionally And to introduced Americas in region. we that

vitamin work P&G, formally that the fairly market that came and that it prenatal been on example, think done include relaunched this a a that's now product from and Americas is years. Merck includes to For nice in choline. And was for forth. I the a in been launched just so new choline just It's of dose

the opportunity regions. real opportunities across nutrition get line globally seeing are the us So specific we interest as each in in see and we of the really a do for goal

Ram Selvaraju

quick just then other two And items. Okay.

emerged whether you front? to already be to European or expect have persist pricing continue that additional potentially might you comment you see trends front, the on monogastric whether On in there can think that improvement on XXXX,

the in at fracking to that anytime exit business going And regard will that line positioning then And or basis? -- in might on potentially soon, Thank appear the you a Balchem's would that business that to some Industrial you been point are reevaluating be you are ensue? look turnaround away still Products entirely, more a you. possibility that's have comprehensive there which Because seen hopeful industry, don't that lastly with the the to strategically be challenges of segment.

Ted Harris

Sure.

from African some in Let's and by this start significantly extent perspective, our swine obviously, they're fever, with much and monogastric impacted China the driven China. to from Europe. by probably And the being is by competitors being And now coronavirus. of

And it's tell. so is guess it's my our part is an fairly is But -- hard really answer the to situation environment and that of uncertain it's relatively I perspective stable.

a of But where seen stable, things some some positive on there. it's want positive with think at minimally it but entirety of the be potentially planning higher to prices quarters few bank. I sure think last that. raw now XXXX. take it's least But certainly signs the to costs We it China, sign which we signs. kind changing not necessarily driven stable about an and the of having seeing may little bit and -- logistics so China encouraging And internal material we're of for the But being of we've out driving because deal to XXX% for by that don't that coronavirus are up we forth within

for fracking, there's comes do the we stabilization continue part clay of an believe feel that do to important choline growth. opportunity market an when if to and we the Relative back is And mix.

said having a from looking always at our strategic we're But lens. businesses that,

and we'll point. opportunity the this we're It selling business future plans actually at think is business space. any and divest it. manufacture choline don't with that just decide similar to investment that look choline, Health it in remaining cost -- did us, which Health versus essentially Animal and that You a is for and to synergistic saw long-term we like we selling continue what strategically is us it manufactures. we're in small the to growth was the very it we of our very divest product in and business. didn't the This Nutrition at and a because relative and But business the feel have But XXXX had so Nutrition the Animal it's growth to complicated underperforming to it we

Ram Selvaraju

Thank Great. you very much.

Operator

Thank you. your with question Please the Ramgopal proceed of next Sidoti. is [Operator with line question. The Mitra Instructions] from

Mitra Ramgopal

taking Good morning. the questions. for Hi. Yes. Thanks

sure if not start the you impact to the the one. of transaction want I'm just to integration for costs quarter. could First give on the and housekeeping

Martin Bengtsson

total of terms just In costs? transaction

Mitra Ramgopal

on impact that from a the Yes, Yeah. dollar.

Martin Bengtsson

a fourth -- sort $X.X in We had about the costs quarter. million Yeah. on $X transaction in fourth of quarter the million

Mitra Ramgopal

then finished. beyond like I the it to And said you the finished Thanks. of that was for on looking with I XX% Okay. the was XX% or it business the know on expect XXXX, sort sounds go ERP, system. have I might but completely that you're maybe wondering just you when early of is is And about that?

Ted Harris

line would what mid-XXXX I to maybe flexibility I time time has fit. at here some today summer. fully as Yeah, late early have see think XXXX this would But acquisition opposed implemented Zumbro is of in us that the targeting point late We I this we've new as what excluding, to line time say we kind we're the say, summer. manage by -- do current

Mitra Ramgopal

Yeah.

Okay.

Martin Bengtsson

Chemogas Our are of plan. the now part

Ted Harris

Yeah.

Mitra Ramgopal

Okay.

to of And to be disruption have we I just back but benefiting Thanks. what ago? little years impact with any to the you think obviously, potentially Ted, clear could similar you early it a it's saw determine Okay. coronavirus, couple too think a on do

Ted Harris

just hard would it Obviously, it's it's watching tough very we're closely to to predict. say, I say. and But

relatively Our limited. direct exposure is

which call sales about of buy it of of somewhat We all into China. million about million materials have are about. China raw from $X $XX We we concerned

some impact seeing with $X million lower orders. are We on that

and our but minor proactive overall a is build a of to that to buffer. bit company's sales. think of starting what of give goods to materials raw little this it's actions We've part just is our taking chain of -- supply bit inventory little trying finished a been impact that a temporary, relatively We

the container to because to starting some from China. of Middle shipments and East, issues see shipping even Europe issues We're in sea availability

So major at I not any it as of describe is impacts mitigating strategies to point, would trying where on as and we're very some well. watching them indirect closely, I there And execute this but said possible. some as

products any customers that as be seen seen. buying But products, could products have to see. China yet of be yet, that more you're and just complexity and upside right, We'll our supplied really direct positive there probably our going The another it's referred versus that's seen, We impact maybe but again, from be who haven't Chinese now But us. look be yet there forward. focused for to to right could positive impacts. some positive sort well of certainly to those ultimately on you there for lift at

Mitra Ramgopal

great. Okay. in was as And real it of then development? No I the to the any updates curious terms just drug on sounds that autism front relates

Ted Harris

you Yes, all relative to on significant update there's to nothing that.

are raising the are But, additional have for of CureMark build and their launch new need plans we with We as the chain report the funds we there. where ultimate significance while to the nothing in prepare work that's and part BLA to to that with trying midst the kind we consultants and for our work order really moving know, forward, of supply I in is process, of that in been, in of our to we product.

Mitra Ramgopal

Okay. And then, how for finally, CapEx we of should think XXXX? -- Martin, I just

Martin Bengtsson

$XX million to million $XX range.

Mitra Ramgopal

me. the Okay. Perfect. That’s Well, questions. again for it for thanks taking

Martin Bengtsson

you. Thank

Ted Harris

Mitra. Thanks,

Operator

Brett Hundley proceed your of question is question. the from with line with Global. Our Seaport next Please

Brett Hundley

Hey. Thank follow-up. you the for

two of Just had them.

look those we'll XXXX should guess, normalized. you or your as be this issues business, a out more as this lap out. from year, XXXX of and we year much some some find would was As QX I plant there in to expect to reminder, expect in But at I QX we well? nutrition just

Martin Bengtsson

specifically, nutrition plant Brett? For

Brett Hundley

yes. That's correct,

Martin Bengtsson

year. we if that obviously, mean, same it have was will help. certainly California the down a And, spring in don't wet I Yes.

during to a expect that India XXXX, their burn destocked much destocking inventory happening they with too so as coming one that customers our you through We year. well the also this inventory normalize had held major that as year, into would of in there

over So to second get it and nutrition. run quarter normal a and plant lap first rate for the back do the more will we I think

I again, back to barring weather guarantee But there, Now, can't normal. I in case. this do be to expect it unusual anything

Brett Hundley

for I QX be model ANH. looking I Okay. to the looking to then, growth, ask mean, you potential sales I'm year-on-year my on a sales strong see in on side particularly segment, the ANH growth wanted I way And performance the and the Martin. at at

have an and QX and easy mono. comp it both sequentially feels real you're building you I just in in momentum mean, ruminant some like

quite if or you strong would by indeed, sales see a at all, wanted number moderate run during QX. and in my could that I I guess, So, you you to believe if growth expectations do you that ANH see

Ted Harris

the absolutely The really exact it's well. couple think really change we've think, in We've your that XM and I a strong numbers, of quarters across growth knowing you're few wins right. market. as fundamental had AminoShure not of ANH I market out Again, and been particularly of launch that’s a had driving

we sustainable. that of combination believe are a all it's things, So

The really a if was strong, performance very year QX last you was strong of quarter. very because recall QX in

do we off the to couple the the growth the of to strong are seem they've level, healthy really prices our of prices momentum to in they lack and now that so, business Europe, through down last having very pleased. and at peaks -- encouraging the year, XXXX's little build the in positive And And that, healthy bit show QX, gains off saw quarters in protein year a some ANH a market a milk continue and of of that Chinese expect And from staying was from are we we but XXXX. building in of given be a that lap strength were level. come out

Brett Hundley

I helpful. That’s it. appreciate

Keep job. great up good doing the are work. guys You

Ted Harris

lot, Thanks I a appreciate Brett. it.

Operator

line proceed Please of next Polak question Capital. Our from is with question. your Tony with the Aegis

Tony Polak

morning. Good

Ted Harris

Hey Tony.

Tony Polak

Phase us when results? there? file the Could of expected a time you on in the line give the what CureMark III update they the little on is terms And actually more timing

Martin Bengtsson

Yes.

paperwork That's filing us predict. again, certainly CureMark But has would exactly expected time our controls that relative place, be that late somewhat all for XXXX file of be into BLA. hard to on maybe So, in of really the time supply getting and the their line it's sort to for we getting XXXX us line that in ready along of CureMark or such order quality to would frame. chain time

we're this at what working that's point. toward So,

Tony Polak

it their And big to is go pharma? assume it to selling Okay. opposed I themselves a as plan to

Martin Bengtsson

but doing, allows them market on looking at help what of go This they no prepared There's I and They concentration to can't communities it maybe of but alone. autism on be alone. Harris' speculation see part, Ted just based in believe market question kind medical go they there is it case are the now that think the are that options. to this they the both we would the

they're think But see it So in but doing we their who definitely they exploring they're and hiring signs or alone. that preparing can't either to will are I what and plans go that they're We're to speculation We're not to certainly But their believe selling a privy or options. that. this bit probably Again, that's we there. board. on of pharma. they're little both licensing not exploring big help that

Tony Polak

you tell know Do planning this you how trying they're at Can me that? Okay. much fundraising? to raise

Martin Bengtsson

exact I number Tony. that that raise. I don't the trying not do to they're know know

Tony Polak

they And do employees have many presently? you know how

Martin Bengtsson

how not many do know have I presently. they employees

think, but sub-XX, I'm not would XXX% speculate I it I of sure that.

Tony Polak

results. Okay. Thanks. Great

Martin Bengtsson

Tony. Thanks,

Operator

and Thank end the I'll reached of floor you. for allotted turn and time, this management we've the of remarks. to back At our portion question closing answer

Ted Harris

be the March know I will Once we you will to let you in again next To attending York Annual conferences attending with non-deal City. continued will New March Yes. on on and our XX XX, headed in be a Conference I'd New to interest your today like the months. show XX. May be Market attending our And thank Boston On all just On we the like Also, joining to also CJS Conference. road XXth for call Farm company. York we in few over BMO City, several JPMorgan Industrials we're

few to to next of hope these we And look XXXX see over otherwise, forward you reporting results May. QX events out in some one the at months. early So, of

So, thanks for joining. again

Operator

concludes This you. Thank conference. today's

participation. at this You Thank may you disconnect for lines time. your your

Balchem (BCPC) 21 Feb 202019 Q4 Earnings call transcript